Current and Future State of US Biosimilars
Fourteen years ago, Congress established a regulatory pathway for biosimilars, direct competitors to branded biologic drugs.
Implications of Cannabis Legalization for the US Federal Budget
Federal legislation to legalize, regulate, and tax cannabis could have significant impacts on the federal budget.
When the TCJA Expires: A Tax Policy Summit
The Committee for a Responsible Federal Budget hosted “a tax policy summit “When the TCJA Expires: A Tax Policy Summit” on March 28, 2024.
MGA Releases Economic Impact Report for Multinational Pharmaceutical Company
In a newly released report, MGA highlights the broad economic impact of Otsuka in the United States.
MGA’s Alex Brill on CNBC’s Squawk Box Discussing Tackling the Tax Gap
Alex Brill joined CNBC’s “Squawk Box” to discuss the IRS’ attempt to crack down on the tax gap.
- Presidential Candidates’ Dueling Child Credit Expansions Explained
- A Tip Exemption Is Not Sound Tax Policy
- Implications of Cannabis Legalization for the US Federal Budget
- Alex Brill Writes to FTC Regarding Interim Pharmacy Benefit Manager Report
- A Balanced Plan for Fiscal Stability and Economic Growth
- Despite Headwinds, Biosimilars Market Is Growing in 2024
- IRS says it will deny most claims of pandemic tax credit for employers
- Trump Talks Taxes and Tariffs
- Beware the Baseline Manipulator
- Patent Thicket Déjà Vu
